|Dr. Leonard S. Schleifer M.D., Ph.D.||Co-Founder, President, CEO & Co-Chairman||7M||N/A||1953|
|Dr. George D. Yancopoulos M.D., Ph.D.||Co-Founder, President, Chief Scientific Officer & Co-Chairman||6.59M||N/A||1960|
|Mr. Robert E. Landry Jr.||Executive VP of Finance & CFO||1.84M||11.1M||1964|
|Dr. Andrew J. Murphy Ph.D.||Executive Vice President of Research||1.62M||19.39M||1959|
|Mr. Daniel P. Van Plew||Executive VP and GM of Industrial Operations & Product Supply||1.95M||45.28M||1973|
|Ms. Marion E. McCourt||Executive Vice President of Commercial||1.5M||4.25M||1960|
|Ms. Patrice Gilooly||Senior Vice President of Quality Assurance & Operations||N/A||N/A||N/A|
|Mr. Christopher R. Fenimore CPA||Senior VP, Head of Accounting & Controller||N/A||N/A||1971|
|Mr. Gerald Underwood||Senior Vice President of Technical Operations||N/A||N/A||N/A|
|Mr. Bob McCowan||Senior VP of IT & Chief Information Officer||N/A||N/A||N/A|
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 10; Compensation: 9.